- Home
- CAN vs CADL Comparison
CAN vs CADL Comparison
Compare CAN & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- CADL
- Stock Information
- Founded
- CAN 2013
- CADL 1999
- Country
- CAN Singapore
- CADL United States
- Employees
- CAN N/A
- CADL N/A
- Industry
- CAN Semiconductors
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- CADL Health Care
- Exchange
- CAN Nasdaq
- CADL Nasdaq
- Market Cap
- CAN 330.5M
- CADL 313.5M
- IPO Year
- CAN 2019
- CADL 2021
- Fundamental
- Price
- CAN $0.81
- CADL $4.84
- Analyst Decision
- CAN Strong Buy
- CADL Strong Buy
- Analyst Count
- CAN 6
- CADL 5
- Target Price
- CAN $2.50
- CADL $19.80
- AVG Volume (30 Days)
- CAN 25.3M
- CADL 697.1K
- Earning Date
- CAN 08-14-2025
- CADL 11-13-2025
- Dividend Yield
- CAN N/A
- CADL N/A
- EPS Growth
- CAN N/A
- CADL N/A
- EPS
- CAN N/A
- CADL N/A
- Revenue
- CAN $345,360,000.00
- CADL N/A
- Revenue This Year
- CAN $90.25
- CADL N/A
- Revenue Next Year
- CAN $42.94
- CADL N/A
- P/E Ratio
- CAN N/A
- CADL N/A
- Revenue Growth
- CAN 82.40
- CADL N/A
- 52 Week Low
- CAN $0.53
- CADL $3.79
- 52 Week High
- CAN $3.27
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- CAN 59.68
- CADL 34.62
- Support Level
- CAN $0.77
- CADL $4.60
- Resistance Level
- CAN $0.85
- CADL $5.01
- Average True Range (ATR)
- CAN 0.04
- CADL 0.29
- MACD
- CAN 0.01
- CADL -0.04
- Stochastic Oscillator
- CAN 77.32
- CADL 15.28
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.